3 terminated, 2 completed, 1 recruiting. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Terminated 3, Completed 2, Recruiting 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
Follow SLL: new trials by email Literature Review of SLL trials Research Report on SLL
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Epcoritamab as a Consolidation Therapy in CLL/SLL Epcoritamab - CLL/SLL, CLL | Phase 2 | Recruiting | Zulfa Omer | 22 | 2025-08-22 | 2026-01-06 |
| Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL TP-0903, TP-0903 and ibrutinib combination therapy - Chronic Lymphocytic Leukemia, CLL | Phase 1 / Phase 2 | Terminated | Sumitomo Pharma America, Inc. | 3 | 2019-06-10 | 2023-11-09 |
| Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) A6 - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | Terminated | Ångstrom Pharmaceuticals | 5 | 2014-02-01 | 2016-07-13 |
| Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL Ofatumumab, High-Dose Methylprednisolone, Alemtuzumab - CLL, SLL | Phase 2 | Terminated | Dana-Farber Cancer Institute | 30 | 2011-12-01 | 2023-08-29 |
| Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma rituximab, bortezomib, cladribine - Lymphoma, Mantle Cell Lymphoma | Phase 2 | Completed | University of Arizona | 24 | 2009-07-07 | 2019-12-30 |
| Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL veltuzumab - NHL, Lymphoma, Non-Hodgkin | Phase 1 / Phase 2 | Completed | Gilead Sciences | 32 | 2008-01-01 | 2021-08-16 |
Leukemia, Lymphocytic, Chronic, B-Cell (5) · Leukemia (2) · Lymphoma (2) · Lymphoma, Follicular (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Leukemia, Prolymphocytic (1) · Lymphoma, B-Cell (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, Non-Hodgkin (1) · Neoplasms (1) · Recurrence (1) · Waldenstrom Macroglobulinemia (1)
Chronic Disease (5) · Disease Attributes (5) · Hematologic Diseases (5) · Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Leukemia, B-Cell (5) · Leukemia, Lymphoid (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Neoplasms by Histologic Type (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Neoplasms (4) · Leukemia (3)
Alemtuzumab (1) · Bortezomib (1) · Cladribine (1) · Methylprednisolone (1) · Rituximab (1) · dubermatinib (1) · ofatumumab (1) · veltuzumab (1)
Dana-Farber Cancer Institute (1) · Gilead Sciences (1) · Sumitomo Pharma America, Inc. (1) · University of Arizona (1) · Zulfa Omer (1) · Ångstrom Pharmaceuticals (1)
United States (6)
Daniel O. Persky, MD (1) · Jennifer R Brown, MD PhD (1) · Michael Choi, MD (1) · Phillip Komarnitsky (1) · William Wegener, MD, PhD (1)
PMID 21173095, PMID 26389849, PMID 29056470, PMID 30322319
P30CA023074 (1)